key: cord-0906550-048w08aj
authors: Chi, Gerald; Lee, Jane J.; Jamil, Adeel; Gunnam, Vamsikrishna; Najafi, Homa; Memar Montazerin, Sahar; Shojaei, Fahimehalsadat; Marszalek, Jolanta
title: Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis
date: 2020-08-03
journal: J Clin Med
DOI: 10.3390/jcm9082489
sha: a8bc404326999fe3ca4293a3cdb4b0a02dae7b1f
doc_id: 906550
cord_uid: 048w08aj

Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may be inadequate to control the increased risk of venous thromboembolism (VTE) in patients hospitalized for coronavirus disease 2019 (COVID-19) infection. Additionally, it remains unclear whether the D-dimer measurement is useful for VTE risk stratification among COVID-19 patients. This study aimed to offer benchmark data on the incidence of VTE and to examine the difference in D-dimer levels among anticoagulated COVID-19 patients with and without VTE incident. Methods: A comprehensive literature review of PubMed from inception to May 2020 was performed for original studies that reported the frequency of VTE and death among COVID-19 patients who received thromboprophylaxis on hospitalization. The endpoints included VTE (a composite of pulmonary embolism (PE) or deep vein thrombosis (DVT)), PE, DVT, and mortality. Results: A total of 11 cohort studies were included. Among hospitalized COVID-19 patients, 23.9% (95% confidence interval (CI), 16.2% to 33.7%; I(2) = 93%) developed VTE despite anticoagulation. PE and DVT were detected in 11.6% (95% CI, 7.5% to 17.5%; I(2) = 92%) and 11.9% (95% CI, 6.3% to 21.3%; I(2) = 93%) of patients, respectively. Patients in the intensive care unit (ICU) had a higher risk for VTE (30.4% )95% CI, 19.6% to 43.9%)) than those in the ward (13.0% (95% CI, 5.9% to 26.3%)). The mortality was estimated at 21.3% (95% CI, 17.0% to 26.4%; I(2) = 53%). COVID-19 patients who developed VTE had higher D-dimer levels than those who did not develop VTE (mean difference, 2.05 µg/mL; 95% CI, 0.30 to 3.80 µg/mL; P = 0.02). Conclusions: The heightened and heterogeneous risk of VTE in COVID-19 despite prophylactic anticoagulation calls into research on the pathogenesis of thromboembolic complications and strategy of thromboprophylaxis and risk stratification. Prominent elevation of D-dimer may be associated with VTE development and can be used to identify high-risk subsets.

endpoints (VTE, PE, deep vein thrombosis (DVT), or mortality) among hospitalized patients with laboratory-confirmed COVID-19 infection who received at least standard doses of thromboprophylaxis with UFH or LMWH were included. All searches were limited to the English language and the time from inception to 31 May 2020.

Data extracted from each study included study design, population, clinical setting (ICU or ward), thromboprophylaxis strategy, patient characteristics, D-dimer levels, follow-up duration, and frequencies for VTE events or deaths. Database search, article screening, and study selection were performed independently by two investigators using a standardized approach. Disagreement in extracted data was adjudicated by a third investigator. A flow diagram depicting the process of the literature search and screening is provided in Figure S1 .

Two independent investigators assessed the quality of cohort studies in accordance with the Newcastle-Ottawa Scale. Disagreement in the quality assessment was resolved by discussion and consensus. The quality assessment criteria and forms were provided in Tables S2 and S3.

Study endpoints include: (1) VTE, defined as a composite of PE or DVT; (2) PE as detected by computed tomography pulmonary angiography in the case of clinical suspicion and/or acute degradation of hemodynamic or respiratory status; (3) DVT of the lower or upper extremity, as detected by ultrasonography in the case of clinical suspicion or from screening; and (4) all-cause mortality.

The first part of the analysis aimed to estimate the incidence of VTE and mortality among hospitalized COVID-19 patients who received thromboprophylaxis. The proportion was deemed as the effect size, and calculated as the number of cases (VTE, PE, DVT, and mortality) divided by the size of the sample. Considering the distribution of observed proportions was skewed and not centered around 0.5, logit transformation was performed to conform to the normal distribution [21] . For each study, the natural logarithm of the proportion was used as an effect size statistic, and the inverse variance of the transformed proportion was used as study weight. Confidence intervals (CIs) of proportions were calculated by normal approximation. The summary effect size was then computed by fitting a random-effects model using the DerSimonian and Laird method. Heterogeneity across the studies was assessed using the Q test (with the threshold of P < 0.10 indicating the presence of heterogeneity) and I 2 statistic (with the values of 0.25, 0.50, and 0.75 indicating a low, moderate, and high degree of heterogeneity, respectively). A subgroup analysis by clinical setting was performed to compare the observed effect size in the ICU setting vs. the ward setting and to test its potential influence on heterogeneity. Funnel plots and an Egger's test were employed to detect small-study effects.

The second part of the analysis aimed to compare the D-dimer level between cases and controls. Two endpoints were studied: VTE and mortality. Cases were defined as patients who developed VTE or died, whereas controls were defined as patients who did not develop VTE or survived. The absolute difference in the mean D-dimer value was deemed as the effect size. For each study, the D-dimer was uniformly expressed as µg/mL, and the mean and standard deviation (SD) were estimated from the median, interquartile range, and sample size [22] . The overall effect size (i.e., mean difference of D-dimer level) was summarized using the inverse variance weighted approach in a random-effects model, with a positive value indicating a higher average level of D-dimer in cases than in controls.

Analysis was performed using the meta package in the R software (Version 3.5.2; the R Foundation for Statistical Computing), and Review Manager (Version 5.3; the Nordic Cochrane Centre, the Cochrane Collaboration).

A total of 1981 subjects from 11 studies were included in the meta-analysis and summarized in Table 1 [19, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] . The majority of studies were retrospective, except for two studies. Five studies were conducted exclusively in the ICU setting, whereas six studies enrolled patients in the ward setting, with 10% to 38% requiring admission to the ICU. The mean age was consistently between 60 and 70 years. The proportion of males ranged from 52% to 81%. Approximately 1% to 7% patients had a history of VTE, and up to 10% of patients had cancer. The follow-up duration varied from 6 to 55 days. Only one study reported bleeding outcomes, in which 4 out of 150 patients (2.7%) had hemorrhagic complications [19] . The quality of the studies was generally high, with scores ranging from 6 to 9 as evaluated with the Newcastle-Ottawa Scale (Tables S2 and S3 ). 

The proportion of COVID-19 patients who underwent thromboprophylaxis and developed VTE was estimated at 23.9% (95% CI, 16.2% to 33.7%; Figure 1 ). The incidence was higher in the ICU setting (30.4% (19.6% to 43.9%)) than in the ward setting (13.0% (5.9% to 26.3%)). Substantial heterogeneity was present within and across the subgroups (I 2 = 88%, 94%, and 93% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 90%). No significant small-study effect was noted by the funnel plot ( Figure S2 ) or Egger's test (P = 0.89; Table S4 ).

The proportion of COVID-19 patients who underwent thromboprophylaxis and developed VTE was estimated at 23.9% (95% CI, 16.2% to 33.7%; Figure 1 ). The incidence was higher in the ICU setting (30.4% (19.6% to 43.9%)) than in the ward setting (13.0% (5.9% to 26.3%)). Substantial heterogeneity was present within and across the subgroups (I 2 = 88%, 94%, and 93% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 90%). No significant small-study effect was noted by the funnel plot ( Figure S2 ) or Egger's test (P = 0.89; Table S4 ). 

Approximately 11.6% (95% CI, 7.5% to 17.5%) of the anticoagulated COVID-19 patients developed PE (Figure 2 ). Similar to VTE, the incidence was higher in the ICU setting (15.7% (9.4% to 25.0%)) than in the ward setting (5.6% (2.4% to 12.4%)). A high degree of heterogeneity was present within and across the subgroups (I 2 = 87%, 75%, and 92% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 85%). No significant small-study effect was noted by the funnel plot ( Figure S3 ) or Egger's test (P = 0.06; Table S4 ). 

Approximately 11.6% (95% CI, 7.5% to 17.5%) of the anticoagulated COVID-19 patients developed PE (Figure 2 ). Similar to VTE, the incidence was higher in the ICU setting (15.7% (9.4% to 25.0%)) than in the ward setting (5.6% (2.4% to 12.4%)). A high degree of heterogeneity was present within and across the subgroups (I 2 = 87%, 75%, and 92% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 85%). No significant small-study effect was noted by the funnel plot ( Figure S3 ) or Egger's test (P = 0.06; Table S4 ). 

The incidence of DVT was estimated at 11.9% (95% CI, 6.3% to 21.3%) among COVID-19 patients with thromboprophylaxis ( Figure 3) . The proportion was similar between the ICU subgroup (10.6% (4.5% to 23.2%)) and the ward subgroup (13.6% (5.2% to 31.1%)). Similarly, substantial heterogeneity was present within and across the subgroups (I 2 = 93%, 93%, and 93% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 93%). Funnel plot asymmetry was noted ( Figure S4 ) and the Egger's test suggested small-study effects (P = 0.0012; Table S4 ). 

The incidence of DVT was estimated at 11.9% (95% CI, 6.3% to 21.3%) among COVID-19 patients with thromboprophylaxis ( Figure 3) . The proportion was similar between the ICU subgroup (10.6% (4.5% to 23.2%)) and the ward subgroup (13.6% (5.2% to 31.1%)). Similarly, substantial heterogeneity was present within and across the subgroups (I 2 = 93%, 93%, and 93% for ICU, ward, and overall) and could not be explained by the clinical setting (residual I 2 = 93%). Funnel plot asymmetry was noted ( Figure S4 ) and the Egger's test suggested small-study effects (P = 0.0012; Table S4 ). 

Six studies were available for analysis of all-cause mortality ( Figure S5 ). Mortality ranged from 11.5% to 30.3%, and was estimated at 21.3% (95% CI, 17.0% to 26.4%) among COVID-19 patients with thromboprophylaxis. There was a moderate heterogeneity across the studies (I 2 = 53%). No significant small-study effect was noted by the funnel plot ( Figure S6 ) or Egger's test (P = 0.18, Table S4 ).

Mean D-dimer levels between cases and controls were compared ( Figure S7 ). Compared with patients who did not develop VTE, a higher level of D-dimer was observed in patients who developed VTE (mean difference, 2.05 µg/mL; 95% CI, 0.30 to 3.80 µg/mL; P = 0.02). The mean difference was not significant between non-survivors and survivors (mean difference, 3.70; 95% CI, −2.32 to 9.72; P = 0.23). Taken together, patients who developed VTE or died had higher D-dimer levels than those who did not develop VTE or survived (mean difference, 2.57; 95% CI, 1.01 to 4.14; P = 0.001). The I 2 values were 64% for VTE and 96% for mortality, suggesting a moderate-to-high and high degree of heterogeneity.

Based on aggregate data from cohort studies, the meta-analysis provides benchmark information on the incidence of VTE among COVID-19 patients who received thromboprophylaxis (summarized in Figure S8 ). Overall, approximately 24% developed VTE (12% developed PE and 12% developed DVT) despite anticoagulation with at least prophylactic dosing. The risks of VTE and PE were both higher in the ICU setting (30% and 16%) than in the ward setting (13% and 6%). In contrast, the risk of DVT was similar in the two settings. The heightened risk of VTE points to an unmet need for intensified or extended thromboprophylaxis for high-risk hospitalized COVID-19 patients, which corroborates with the recent advocacy of intermediate-dose LMWH (e.g., enoxaparin, 40-60 mg daily or 40 mg twice daily, especially for BMI > 30 kg/m 2 ) by institutional antithrombotic protocols [32] . Only 1 of the 11 included studies reported bleeding outcomes. Unlike the acutely ill medical patients 

Six studies were available for analysis of all-cause mortality ( Figure S5 ). Mortality ranged from 11.5% to 30.3%, and was estimated at 21.3% (95% CI, 17.0% to 26.4%) among COVID-19 patients with thromboprophylaxis. There was a moderate heterogeneity across the studies (I 2 = 53%). No significant small-study effect was noted by the funnel plot ( Figure S6 ) or Egger's test (P = 0.18, Table S4 ).

Mean D-dimer levels between cases and controls were compared ( Figure S7 ). Compared with patients who did not develop VTE, a higher level of D-dimer was observed in patients who developed VTE (mean difference, 2.05 µg/mL; 95% CI, 0.30 to 3.80 µg/mL; P = 0.02). The mean difference was not significant between non-survivors and survivors (mean difference, 3.70; 95% CI, −2.32 to 9.72; P = 0.23). Taken together, patients who developed VTE or died had higher D-dimer levels than those who did not develop VTE or survived (mean difference, 2.57; 95% CI, 1.01 to 4.14; P = 0.001). The I 2 values were 64% for VTE and 96% for mortality, suggesting a moderate-to-high and high degree of heterogeneity.

Based on aggregate data from cohort studies, the meta-analysis provides benchmark information on the incidence of VTE among COVID-19 patients who received thromboprophylaxis (summarized in Figure S8 ). Overall, approximately 24% developed VTE (12% developed PE and 12% developed DVT) despite anticoagulation with at least prophylactic dosing. The risks of VTE and PE were both higher in the ICU setting (30% and 16%) than in the ward setting (13% and 6%). In contrast, the risk of DVT was similar in the two settings. The heightened risk of VTE points to an unmet need for intensified or extended thromboprophylaxis for high-risk hospitalized COVID-19 patients, which corroborates with the recent advocacy of intermediate-dose LMWH (e.g., enoxaparin, 40-60 mg daily or 40 mg twice daily, especially for BMI > 30 kg/m 2 ) by institutional antithrombotic protocols [32] . Only 1 of the 11 included studies reported bleeding outcomes. Unlike the acutely ill medical patients [33] , the benefit-risk tradeoff (i.e., preventing VTE while maintaining an acceptable risk of bleeding) of anticoagulation has not been formally studied in the context of hospitalized COVID-19 patients. Several randomized trials are underway to investigate the efficacy and safety of intermediate-or therapeutic-dose versus prophylactic-dose LMWH in hospitalized COVID-19 patients, such as COVID-HEP (ClinicalTrials.gov Identifier: NCT04345848), IMPROVE (ClinicalTrials.gov Identifier: NCT04367831), and HEP-COVID (ClinicalTrials.gov Identifier: NCT04401293). Results from these studies will inform antithrombotic strategies for COVID-19 patients.

There are important caveats to heed when interpreting the data on VTE incidence among COVID-19 patients. Pulmonary vessel occlusion in COVID-19 patients might result from embolism, thrombosis, or the combination of both. On pulmonary angiography, filling defects of pulmonary vessels may represent reminiscent of in situ microthrombi that also exist in non-pulmonary organs and constitute a part of multi-organ failure. [34] As the occlusion detected by CTPA may not be exclusively caused by embolism, the incidence of PE from the present analysis could be overestimated. Autopsy studies have reported pulmonary vessel occlusion of embolic and thrombotic origin in COVID-19 patients. Specifically, Wichmann et al. described massive PE associated with fresh thrombi in the prostatic venous plexus among one-third of autopsied patients [35] . In contrast, Lax et al. described thrombotic occlusion of small and mid-sized pulmonary arteries without apparent embolism in all autopsied patients [36] . Unlike macro-thrombosis in PE that is featured by excessive thrombin generation and aggravated by the imbalance between pro-and anti-coagulant factors, pulmonary micro-thrombosis is hallmarked by altered alveoli and pulmonary microvasculature associated with platelet/ultra-large von Willebrand factor multimers anchored to the injured endothelium and intra-alveolar fibrin deposition, which develops as a consequence of endotheliopathy due to direct viral infection and immune-mediated host response [37, 38] . Therapeutic implications of distinctive pathogenesis between pulmonary embolism and pulmonary thrombosis should be further investigated. As anticoagulation is generally not indicated for the treatment of thrombotic microangiopathy with the exception of antiphospholipid syndrome [39] , aggressive thromboprophylaxis may not translate into improved efficacy but pose an increased risk of hemorrhagic complications [34] .

Substantial heterogeneity was observed in the VTE composite and its components. The heterogeneity was not mitigated by stratification by clinical setting (residual I 2 > 75%), and may be related to the different VTE risk profile and clinical severity of patients across the studies. The heterogeneity in VTE risk suggests that the COVID-19 patients may represent a population with heterogeneous predisposition to thrombosis. Alternatively, it may reflect the difference in the methodology employed to identify VTE across the studies on COVID-19 patients. For instance, the indications for VTE detection could differ among the studies, and include clinical parameters (e.g., worsening PaO2/FiO2 despite inhaled nitric oxide or after prone positioning, hemodynamic deterioration requiring fluid challenge and/or increased norepinephrine infusion rate, or dilated right ventricle without acute cor pulmonale), laboratory assessment (e.g., significant or rapid elevation of D-dimer values despite anticoagulation), or both (Table 1) . Furthermore, the timing and frequency of performing diagnostic imaging could also contribute to heterogeneity. This observation highlights the need for standardized VTE diagnostic and management approaches to hospitalized or critically ill COVID-19 patients.

Thus far, few studies provided insights into baseline VTE risk assessment of hospitalized COVID-19 patients. A report of a nationwide dataset from China showed that 40% of COVID-19 patients were at high risk for VTE as evaluated by the Padua prediction score (PPS) [40] . Another single-institution study from China reported that 66% of the COVID-19 patients were in the high-risk group (PPS ≥ 4), and DVT was identified more frequently in the high-risk group than the low-risk patients (62.8% vs. 14.3%) [31] . Furthermore, the combined use of CURB-65 score 3-5, PPS ≥ 4, and D-dimer > 1.0 µg/mL yielded a sensitivity of 88.5% and specificity of 61.4% for DVT. Prior to the COVID-19 pandemic, the incorporation of D-dimer into VTE risk assessment model has been shown to identify high-risk subsets that benefit from extended-duration thromboprophylaxis [41, 42] . Although the D-dimer level is commonly elevated in COVID-19 infection [43] , the present analysis demonstrated that COVID-19 patients who developed VTE had markedly higher D-dimer levels than those who did not develop VTE, with a mean difference of approximately 4 times the upper limit of normal (ULN). It should be noted that a conventional D-dimer cut-off of 0.5 µg/mL may have inadequate specificity for predicting adverse outcomes or guiding anticoagulation decisions in COVID-19 patients. In a multicenter cohort study of adult inpatients with COVID-19, a D-dimer > 1.0 µg/mL was associated with 18-fold increased odds for in-hospital death, while the association was not significant with >0.5 µg/mL [5] . Additionally, the study by Tang et al. showed that the effect of heparin on reducing 28-day mortality was significant in patients with a D-dimer > 6-fold of ULN but not in the overall study population. However, D-dimer measurement may not be routinely performed in hospitalized patients. A recent meta-analysis indicated that other commonly available biomarkers (such as hemoglobin and albumin) could assist risk stratification for severe and fatal COVID-19 [44] . Decreased hemoglobin or albumin levels may reflect underlying inflammation or disease states that predispose patients to thrombosis. Moreover, D-dimer (>1.0 µg/mL), anemia (<12.5 g/dL for males; <11.0 g/dL for females), and hypoalbuminemia (<3.5 g/dL) were demonstrated to have comparable magnitude of association with VTE in acutely ill hospitalized patients who received thromboprophylaxis [45] [46] [47] . Further research is needed to investigate the incremental prognostic value of these biomarkers and the optimal cut-offs in COVID-19 patients.

Several limitations should be considered. First, information about the comparative efficacy and safety of thromboprophylaxis strategies was unavailable. Second, most of the included studies were retrospective. Third, the decision to perform computed tomography pulmonary angiography or ultrasonography was at the discretion of the treating physicians, and ascertainment bias cannot be excluded. Fourth, the majority of the included studies evaluated the incidence of VTE events that occurred during hospital stay and followed the patients for a relatively short duration. However, a cohort study of medically ill hospitalized patients using administrative claims database showed that 56.6% of the VTE events occurred after discharge [48] . This finding is supported by another population-based study which demonstrated that approximately one-half of the VTE events were related to current or recent hospitalization, and a total of 75% of the VTE events developed after hospital discharge, with a median time to develop VTE of 19.5 days [49] . Indeed, the risk of VTE may extend beyond the standard course of anticoagulation, and VTE events may occur after hospital discharge due to lack of anticoagulation coverage and lead to recurrent hospitalization [50] . To better capture the time course of hospital-associated VTE, future studies should consider extending the follow-up duration to at least 90 days. Last, only two studies were available for examining the association of the D-dimer with mortality in the analysis. The insignificant difference in the D-dimer between non-survivors and survivors may reflect a lack of statistical power. Despite these limitations, the present meta-analysis represents a synthesis of the currently available data.

The heightened and heterogeneous risk of VTE in COVID-19 despite prophylactic anticoagulation calls for research on the pathogenesis of thromboembolic complications and the strategy of thromboprophylaxis and risk stratification. Marked elevation of D-dimer levels may be associated with VTE development and can be used to identify high-risk subsets. Prospective randomized clinical trials are warranted to investigate the comparative efficacy and safety of anticoagulation strategies.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/8/2489/s1, Figure S1 : PRISMA flow diagram, Figure S2 : Funnel plot of VTE, Figure S3 : Funnel plot of PE, Figure S4 : Funnel plot of DVT, Figure S5 : Rate of mortality among COVID-19 patients undergoing thromboprophylaxis, Figure S6 : Funnel plot of mortality, Figure S7 : Mean difference in D-dimer between cases and controls, Figure S8 : Summary of VTE incidence by clinical setting, Table S1 : Search strategy, Table S2 : Quality assessment criteria for cohort studies, Table S3 : Quality assessment form for cohort studies, Table S4 : Summary of Egger's test for small-study effect. 

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis

COVID-19 and its implications for thrombosis and anticoagulation

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism

Venous thromboembolism and its prevention in critical care

High risk of the critically ill for venous thromboembolism

Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in the critically ill

Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France

Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: An APEX trial substudy

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Practical Guidance for the Prevention of Thrombosis and Management of Coagulopathy and Disseminated Intravascular Coagulation of Patients Infected with COVID-19

Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance; WHO/nCoV/Clinical/2020.3; World Health Organization

High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: Incidence and role of D-dimer as predictive factors

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease

Emergence of institutional antithrombotic protocols for coronavirus 2019

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: A bivariate analysis

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results from a Prospective

Endothelial cell infection and endotheliitis in COVID-19

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

Thrombotic microangiopathies: Similar presentations, different therapies. Cleve Clin

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial

Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy

Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial

Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients

Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated with Venous Thromboembolism among Acutely Ill Hospitalized Medical Patients: Findings from the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban Trial)

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license